MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Rockwell Medical Cash Conversion Cycle 2011-2026 | RMTI
Annual Cash Conversion Cycle Rockwell Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45 | 36.1 | 30 | 23 | 28.9 | 39.8 | 63.7 | 93.1 | 63.8 | 19.1 | -15.1 | -70.6 | 7.38 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 93.1 | -70.6 | 28 |
Quarterly Cash Conversion Cycle Rockwell Medical
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64 | 65.2 | - | 43.8 | 46.6 | 50.1 | - | 31.4 | 29.6 | 34.2 | - | 48.4 | 46.7 | 41.3 | - | 29.5 | 37.7 | 33.5 | - | 4.86 | 4.87 | 7.56 | - | 28.6 | 29.9 | 33.3 | - | 35.4 | 40.5 | 49.3 | - | 62.6 | 70.3 | 39.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 70.3 | 4.86 | 38.8 |
Cash Conversion Cycle of other stocks in the Drug manufacturers industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-38 | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
-128 | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
460 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-206 | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-224 | - | 0.86 % | $ 117 M | USA |
 |
Aurora Cannabis
ACB
|
1.45 K | $ 3.29 | -0.6 % | $ 86.3 M |  Canada |
 |
China Pharma Holdings
CPHI
|
164 | $ 0.63 | 0.3 % | $ 11 M |  China |
 |
Catalent
CTLT
|
110 | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
137 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
192 | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
213 | $ 2.51 | -0.33 % | $ 1.31 B | Canada |
 |
DURECT Corporation
DRRX
|
41.4 | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
181 | $ 7.98 | -0.87 % | $ 409 M | USA |
 |
Endo International plc
ENDP
|
141 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
45.7 | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
775 | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-161 | $ 3.05 | - | $ 42.9 M | USA |
 |
Bausch Health Companies
BHC
|
78.9 | $ 4.99 | -2.35 % | $ 1.82 B | Canada |
 |
Harrow Health
HROW
|
18.3 | $ 34.02 | 0.05 % | $ 1.25 B | USA |
 |
OptiNose
OPTN
|
314 | - | - | $ 1.08 B | USA |
 |
Evolus
EOLS
|
74.8 | $ 4.54 | -3.1 % | $ 293 M | USA |
 |
Pacira BioSciences
PCRX
|
209 | $ 22.49 | -0.71 % | $ 1.04 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
139 | - | -39.89 % | $ 27.7 M | USA |
 |
Assertio Holdings
ASRT
|
467 | $ 14.91 | 6.5 % | $ 95.5 M | USA |
 |
Canopy Growth Corporation
CGC
|
177 | $ 0.95 | -2.29 % | $ 102 M | Canada |
 |
OrganiGram Holdings
OGI
|
2.92 K | $ 1.35 | -0.74 % | $ 402 M | Canada |
 |
PetIQ
PETQ
|
53.8 | - | 1.64 % | $ 400 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
150 | $ 2.42 | -5.1 % | $ 3 M | USA |
 |
PLx Pharma
PLXP
|
111 | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
96 | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
-21.1 | - | - | $ 33.6 M | USA |
 |
Radius Health
RDUS
|
-53.5 | - | - | $ 1.42 B | USA |
 |
Lannett Company
LCI
|
173 | - | 1.15 % | $ 7.11 M | USA |
 |
Tilray
TLRY
|
169 | $ 6.41 | -0.7 % | $ 3.96 B | Canada |
 |
SCYNEXIS
SCYX
|
106 | $ 0.9 | 3.23 % | $ 44.9 M | USA |
 |
TherapeuticsMD
TXMD
|
-723 | $ 2.31 | - | $ 24.1 M | USA |
 |
Veru
VERU
|
6.7 | $ 2.29 | -0.43 % | $ 309 M | USA |
 |
Viatris
VTRS
|
155 | $ 13.2 | -0.68 % | $ 15.8 B | USA |
 |
Organogenesis Holdings
ORGO
|
64.5 | $ 2.42 | -2.23 % | $ 319 M | USA |
 |
Perrigo Company plc
PRGO
|
137 | $ 9.43 | -1.46 % | $ 1.31 B | USA |
 |
cbdMD
YCBD
|
92 | $ 0.76 | -1.19 % | $ 3.28 M | USA |
 |
Recro Pharma
REPH
|
105 | - | -4.76 % | $ 65.3 M | USA |